By Adria Calatayud Novo Nordisk struck a licensing deal valued at up to $2.1 billion to gain access to oral drug-delivery technologies developed by U.S. startup Vivtex, as the Danish drugmaker...
By Adria Calatayud
Novo Nordisk struck a licensing deal valued at up to $2.1 billion to gain access to oral drug-delivery technologies developed by U.S. startup Vivtex, as the Danish drugmaker move… [+2121 chars]
.jpeg?trim=0,1,0,0&width=1200&height=800&crop=1200:800)
